<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82178">
  <stage>Registered</stage>
  <submitdate>30/07/2007</submitdate>
  <approvaldate>2/08/2007</approvaldate>
  <actrnumber>ACTRN12607000396426</actrnumber>
  <trial_identification>
    <studytitle>Transfer of parecoxib into breast milk; a study of post-operative use following caesarean section.</studytitle>
    <scientifictitle>A study of post-operative precoxib following caesarean section to evaluate the transfer of parecoxib into breast milk.</scientifictitle>
    <utrn />
    <trialacronym>TROPIC</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Parecoxib transfer into breast milk</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Breast feeding</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single dose of parecoxib 40mg intravenously on day 3 or 4 post caesarean section administered to women receiving a conventional non steroidal anti inflammatory drug for routine post-operative analgesia.
Four breast milk (colustrum) samples will be taken over the 24 hours following the dose and a single maternal blood sample approx 6-8 hours post dose (coinciding with one of the breast milk samples).</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Relative Infant dose of parecoxib and valdecoxib (active metabolite) - via pharmacokinetic analysis.
</outcome>
      <timepoint>Four breast milk samples will be taken during the 24 hours after the parecoxib dose ( randomised sample times - at zero, 1, 2, 4, 6, 8, 12, and 24 hours post dose - but one to coincide with the blood sample taken at 6-8 hours post dose).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Infant wellbeing - by means of a neuroadaptive capacity score - range 0-40
</outcome>
      <timepoint>Zero and 24 hours post dose.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Women post caesarean section requiring conventional non steroidal inflammatory drugss for analgesia on day 3 or 4 following delivery.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known hypersensitivity to parecoxib or allergy to sulphonamidesrenal dysfunctionknown past or current peptic ulcer disease or gastro-oesophageal refluxhypertensionNSAID or aspirin induced asthmaischaemic heart disease or cerebrovascular diseasewomen with a preterm infant or an infant requiring care in the neonatal nursery&lt; 18 years of age.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>13/08/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Michael Paech</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Australia and New Zealand College of Anaesthetists Project grant</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to determine the extent of transfer of parecoxib into human breast milk. It is hoped to demonstate that the infant doses of parecoxib received in breast milk of women in early stage lactation and receiving this drug for pain control are not sufficient to cause concern about adverse effects in the neonate.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>King Edward Memorial Hospital for Women</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Melanie Thew</name>
      <address>Department of Anaesthesia and Pain Medicine
King Edward Memorial Hospital for Women
374 Bagot Road
Subiaco WA 6008</address>
      <phone>08 9340 2222</phone>
      <fax />
      <email>melanie.thew@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Michael Paech</name>
      <address>Department of Anaesthesia and Pain Medicine
King Edward Memorial Hospital for Women
374 Bagot Road
Subiaco WA 6008</address>
      <phone>08 9340 2222</phone>
      <fax />
      <email>michael.paech@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>